Cargando…
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
The role of angiogenesis as a mediator of immune regulation in the tumor microenvironment has recently come into focus. Furthermore, emerging evidence indicates that immunotherapy can lead to immune-mediated vasculopathy in the tumor, suggesting that the tumor vasculature may be an important interfa...
Autores principales: | Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585112/ https://www.ncbi.nlm.nih.gov/pubmed/26442214 http://dx.doi.org/10.3389/fonc.2015.00202 |
Ejemplares similares
-
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
por: Naik, Girish S., et al.
Publicado: (2019) -
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021) -
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022) -
Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020) -
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)